Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Drugmakers Allowed To Advise Doctors on Off-Label Uses, Says FDA

Posted by Chrissie Cole
Monday, January 12, 2009 11:43 PM EST
Category: Major Medical
Tags: FDA and Prescription Drugs, Protecting Your Family, Medical Devices, Off-Label, Merck & Co.

LEARN MORE

IMAGE SOURCE:© FDA Web site logo

New guidelines by U.S. health officials allowing pharmaceutical companies to distribute medical journal articles for the purpose of promoting unapproved uses of medicines, has been finalized.

Criticized by lawmakers as being too lax, the guidelines allow companies such as Merck & Co. and GlaxoSmithKline to tell doctors about unapproved uses of medicines– even when it involves off-label uses that have not been approved by the U.S. Food and Drug Administration (FDA).

Off-label use refers to the practice of prescribing drugs for a purpose outside the range of a drug’s approved label. Once the drug is approved, the FDA does not regulate usage and the doctor is able to make a decision based on his or her best judgment.

Manufacturers are barred from marketing their drugs for uses that have not been approved by the FDA.

Nearly one-fifth of all drugs are prescribed for off-label use. Risperdal, a well known antipsychotic, is one such example. The drug is increasingly being prescribed to children for off label use in attention deficit hyperactivity disorder (ADHD) for which it is not approved. And there are several more instances of well known drugs that are prescribed for off-label use.

Congressional Democrats and drug industry critics objected when the policy was first proposed last year.

Opponents argue the distribution of journal articles promotes untested uses of drugs and will fundamentally undermine requirements that mandate companies to prove each new use is safe and effective.

In September 2006, the law expired and drugmakers have been fighting to have it renewed ever since.

Some drug industry critics are concerned about the reliability of such articles. In April, Merck & Co. came under fire when the company was accused of ghostwriting articles about Vioxx (rofecoxib), its painkiller which was withdrawn in 2004 due to safety reasons.

Reports claimed the company helped create the study on Vioxx and then paid academics or leaders in the medical field to lend their name as the lead author. The company denied the allegations, referring to them as false and misleading.

The new guidelines discourage ghostwriting and specifically recommends companies disclosing any financial ties or affiliations with article authors, the FDA said.

Overall, the agency favors distribution of articles that include unapproved uses of drugs and medical devices.

The new guidelines will help medical professionals to receive accurate and timely medical information while avoiding the tedious process of securing FDA approval for expanded use, said a spokesman for the Pharmaceutical Research and Manufacturers of America. #


No Comments

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes